Medications & Treatments
Explainer
The Evidence-Based Guide: Comparing Non-Pharmacological Treatments for Chronic Low Back Pain
10 sources · 7d ago
Explainer
FDA Approves Dual-Targeted Therapy for HER2-Positive Gastric Cancer First-Line Treatment
4 sources · 12d ago
Explainer
Stem Cell Therapy Reverses Severe Heart Failure in 90% of Patients in Landmark Phase 2 Trial
5 sources · 17d ago
More in Medications & Treatments
Multiple MyelomaExplainer
U.S. FDA Approves Zenbexus, First-in-Class CELMoD Therapy, for Relapsed Multiple Myeloma
Clinical Oncologists 40%Regulatory & Trial Experts 35%Health Economists 25%
8 sources · 23d ago
Type 1 DiabetesMedical Breakthrough
FDA Approves First Drug to Preserve Insulin Production After Type 1 Diabetes Diagnosis
Pediatric Endocrinologists 47%Patient Advocacy Groups 35%Regulatory Watchdogs 18%
7 sources · 35d ago
Obesity CareExplainer
FDA Approves First Oral, Non-Peptide GLP-1 for Obesity, Ending Need for Fasting
Clinical Endocrinologists 41%Pharmaceutical Manufacturers 29%Patient Access Advocates 29%
7 sources · 35d ago
Thyroid Eye DiseaseExplainer
FDA Approves Lumvoa, First IGF-1R Inhibitor to Treat Thyroid Eye Disease
Clinical Ophthalmologists 35%Patient Advocacy Groups 35%Industry Analysts 30%
5 sources · 66d ago
PROTAC TherapiesExplainer
FDA Approves Veppanu, the First 'Protein Degrader' Therapy for Advanced Breast Cancer
Clinical Oncologists 40%Biotech Analysts 30%Patient Advocates 30%
6 sources · 74d ago
ExplainerWomen's Health
The Science of Period Pain: Why You Might Be Buying the Wrong Relief
Medical Consensus 45%Patient Advocates 35%Consumer Behavior Analysis 20%
5 sources · 84d ago
ExplainerObesity Treatment
GLP-1s vs. Diet and Exercise: The Evidence-Based Guide to Weight Loss Trade-Offs
Medical Consensus 40%Lifestyle & Longevity Advocates 35%Patient Experience 25%
3 sources · 92d ago
AnalysisGLP-1 Microdosing
The Rise of 'Microdosing' GLP-1 Medications: Wellness Trend or Medical Risk?
Metabolic Optimizers 40%Clinical Skeptics 35%Access Advocates 25%
2 sources · 99d ago